Ar­cutis pulls in a win for its top­i­cal ver­sion of an old As­traZeneca drug in plaque pso­ri­a­sis

Make way, Der­ma­vant. Two months af­ter the com­pa­ny vowed to up­end the plaque pso­ri­a­sis mar­ket with its new­ly ap­proved van­ish­ing cream, there’s an­oth­er top­i­cal to …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER